AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19923206 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from leaders
Number of subjects: 0
Study 19923206 — intervention group
Group type: EXPERIMENTAL
Intervention: Research on supervision strategies
Number of subjects: 0
Study 19923368 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA intake
Number of subjects: 105
Study 19923368 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA intake
Number of subjects: 105
Study 19923368 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA) intake
Number of subjects: 105
Study 19923369 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA intake
Number of subjects: 21
Study 19923369 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA intake
Number of subjects: 21
Study 19923369 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA intake
Number of subjects: 21
Study 19923369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo incubation with different fatty acids
Number of subjects: 21
Study 19923375 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folate/d
Number of subjects: 152
Study 19923375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 19923376 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized vending machine system
Number of subjects: 12
Study 19923475 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with isoniazid, gatifloxicin, levofloxacin, and moxifloxacin
Number of subjects: 0
Study 19923475 — intervention group
Group type: COMPARATOR
Intervention: Rifampin-based regimen
Number of subjects: 0
Study 19926602 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms (CES-D score >or=16)
Number of subjects: 958
Study 19926602 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms (CES-D score >or=24)
Number of subjects: 958
Study 19926602 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint (death or readmission for HF)
Number of subjects: 958
Study 19926602 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D score
Number of subjects: 958
Study 19926602 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms
Number of subjects: 958
Study 19929182 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with GP every three months
Number of subjects: 361
Study 19929182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription redemption for ACE inhibitor or angiotensin-II receptor antagonist
Number of subjects: 361
Study 19929182 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial BP
Number of subjects: 361
Study 19929434 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (TPTD) 20 microg/day subcutaneously
Number of subjects: 10
Study 19930156 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR2-169 peptide vaccine combined with gemcitabine (1000 mg/m² on days 1, 8, and 15 in a 28-day cycle)
Number of subjects: 18
Study 19930156 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR2-169 peptide vaccine combined with gemcitabine
Number of subjects: 18
Study 19930156 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGFR2-169 peptide vaccine
Number of subjects: 18
Study 19930599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (10 mg/body/day) and 5-FU (500 mg/body/day) with radiation (50.4-66 Gy)
Number of subjects: 33
Study 19930599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin and 5-FU with radiation
Number of subjects: 33
Study 19931137 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m² IV and oxaliplatin 130 mg/m² IV every 21 days
Number of subjects: 32
Study 19932054 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX-B (bevacizumab 10 mg/kg, gemcitabine 1000 mg/m(2), oxaliplatin 85 mg/m(2))
Number of subjects: 35
Study 19932054 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX-B
Number of subjects: 35
Study 19932729 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.6 g cis-9,trans-11 CLA and 4.7 g trans-10,cis-12 CLA isomers daily for 3 weeks
Number of subjects: 20
Study 19933192 — intervention group
Group type: COMPARATOR
Intervention: Ocular ischemic syndrome (OIS)
Number of subjects: 13
Study 19933938 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II continuous-flow left ventricular assist device
Number of subjects: 309
Study 19933939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 26
Study 19933939 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 26
Study 19933994 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg daily) plus folic acid (400 microg daily), n = 25
Number of subjects: 50
Study 19933994 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 25
Number of subjects: 50
Study 19936297 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% permethrin for scabies treatment and referral for pyoderma treatment according to guidelines.
Number of subjects: 2329
Study 19936297 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass scabies treatment with 5% permethrin cream offered to all community residents.
Number of subjects: 2329
Study 19937992 — intervention group
Group type: EXPERIMENTAL
Intervention: MIGTS
Number of subjects: 168
Study 19939200 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma human HGF (hHGF) concentrations assessed at admission and 24 hours later
Number of subjects: 104
Study 19939200 — intervention group
Group type: EXPERIMENTAL
Intervention: hHGF levels in STEMI patients
Number of subjects: 104
Study 19940224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia-related driving mishaps
Number of subjects: 452
Study 19940224 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving mishaps
Number of subjects: 452
Study 19940961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based structured intervention
Number of subjects: 0
Study 19940961 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 19946370 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine opt-out HIV testing offered immediately (same day)
Number of subjects: 323
Study 19946370 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine opt-out HIV testing offered early (next day)
Number of subjects: 323
Study 19946370 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine opt-out HIV testing offered delayed (7 days)
Number of subjects: 323
Study 19946371 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate testing (same day, n = 103)
Number of subjects: 298
Study 19946371 — intervention group
Group type: EXPERIMENTAL
Intervention: Early testing (next day, n = 98)
Number of subjects: 298
Study 19946371 — intervention group
Group type: COMPARATOR
Intervention: Delayed testing (7 days, n = 97)
Number of subjects: 298
Study 19946413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/day
Number of subjects: 22
Study 19946413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/day
Number of subjects: 22
Study 19946413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/day and 300 mg/day
Number of subjects: 22
Study 19946413 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib
Number of subjects: 22
Study 19948045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index-guided anesthesia (target range, 40 to 60)
Number of subjects: 6000
Study 19948045 — intervention group
Group type: COMPARATOR
Intervention: End-tidal anesthetic gas-guided anesthesia (target range, 0.7 to 1.3 age-adjusted minimum alveolar concentration)
Number of subjects: 6000
Study 19948045 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral index-guided anesthesia
Number of subjects: 6000
Study 19948045 — intervention group
Group type: COMPARATOR
Intervention: End-tidal anesthetic gas-guided anesthesia
Number of subjects: 6000
Study 19950084 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective heart transplantation (HTX)
Number of subjects: 0
Study 19950084 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients with heart failure
Number of subjects: 0
Study 19950084 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe heart failure (NYHA class IV)
Number of subjects: 0
Study 19951974 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric monitoring of candidate leukemic stem cells (LSC) defined by the immunophenotype CD34+CD38lowCD19+
Number of subjects: 48
Study 19952143 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine
Number of subjects: 797
Study 19952143 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir DF-emtricitabine
Number of subjects: 797
Study 19952143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 797
Study 19953376 — intervention group
Group type: EXPERIMENTAL
Intervention: Best possible invasive therapy (endovascular, neurosurgical, and/or radiation therapy)
Number of subjects: 800
Study 19953376 — intervention group
Group type: COMPARATOR
Intervention: Medical management without intervention
Number of subjects: 800
Study 19953837 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in sports teams
Number of subjects: 717
Study 19954265 — intervention group
Group type: EXPERIMENTAL
Intervention: Q2W darbepoetin alfa
Number of subjects: 104
Study 19955104 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 204
Study 19955196 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 9-cis-beta-carotene (four capsules daily for 90 days)
Number of subjects: 7
Study 19956459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg once daily
Number of subjects: 1051
Study 19956459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg once daily
Number of subjects: 1051
Study 19956459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1051
Study 19956459 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (both doses)
Number of subjects: 1051
Study 19958862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 1373
Study 19959119 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation (63.8%) or CRT with defibrillator (36.2%)
Number of subjects: 15221
Study 19959652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic spine manipulation (thrust and nonthrust manipulations)
Number of subjects: 80
Study 19959652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic spine manipulation
Number of subjects: 80
Study 19962985 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin (264.3 +/- 25 mU/L)
Number of subjects: 29
Study 19962985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose
Number of subjects: 29
Study 19963351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (enteral nutrition)
Number of subjects: 1831
Study 19963351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (parenteral nutrition)
Number of subjects: 1831
Study 19963351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support (overall)
Number of subjects: 1831
Study 19963351 — intervention group
Group type: COMPARATOR
Intervention: No nutritional support
Number of subjects: 1831
Study 19965642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 0
Study 19965657 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan conditioning and MFGS retroviral vector encoding gp91(phox)
Number of subjects: 3
Study 19965662 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium 200 mg twice daily
Number of subjects: 68
Study 19995118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway PV System
Number of subjects: 172
Study 19995432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch concept in acute stroke treatment using perfusion imaging (PI) with a fixed dosage of 5 ml 1 M Gadobutrol.
Number of subjects: 1200
Study 19995432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch concept in acute stroke treatment using perfusion imaging (PI).
Number of subjects: 1200
Study 19995444 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR treatment to left forehead (F3)
Number of subjects: 10
Study 19995444 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR treatment to right forehead (F4)
Number of subjects: 10
Study 19995444 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR treatment (on condition)
Number of subjects: 10
Study 19995444 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (light off)
Number of subjects: 10
Study 19996412 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (mean dose 32.6 mg/kg per day) in the cardiac iron reduction arm
Number of subjects: 192
Study 19996412 — intervention group
Group type: COMPARATOR
Intervention: Control group (prevention arm)
Number of subjects: 192
Study 19996872 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-containing hormone therapy after the age of 60 years
Number of subjects: 0
Study 19996872 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy in middle-aged women before the age of 60 years
Number of subjects: 0
Study 19996872 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens after surgical menopause
Number of subjects: 0
Study 19996872 — intervention group
Group type: COMPARATOR
Intervention: Natural menopause transition
Number of subjects: 0
Study 19996872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy initiation in old age
Number of subjects: 0
Study 19996872 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlife estrogen therapy
Number of subjects: 0
Study 19996998 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral knee extensor endurance training for 6 weeks in HC
Number of subjects: 24
Study 19996998 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral knee extensor endurance training for 6 weeks in CHF
Number of subjects: 24
Study 20001658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs (LLD) for >3 months (stable medication >6 weeks)
Number of subjects: 14478
Study 20001658 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 14478
Study 20001658 — intervention group
Group type: EXPERIMENTAL
Intervention: Good treatment adherence
Number of subjects: 14478
Study 20001658 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal body mass index
Number of subjects: 14478
Study 20001658 — intervention group
Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 14478
Study 20001658 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having metabolic syndrome
Number of subjects: 14478
Study 20001856 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide-containing therapy (including 2 reverse-transcriptase inhibitors and a ritonavir-boosted protease inhibitor) for at least 48 weeks
Number of subjects: 19
Study 20003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal thickness measured by optical coherence tomography (OCT)
Number of subjects: 31
Study 20003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Microperimetry measurements
Number of subjects: 31
Study 20003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoid changes in the outer plexiform and inner nuclear layer
Number of subjects: 31
Study 20003108 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of epiretinal membrane
Number of subjects: 31
Study 20003260 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 171
Study 20003269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin (400 mg bid)
Number of subjects: 28
Study 20003457 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r-based cART
Number of subjects: 1299
Study 20003507 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 56
Study 20003832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant, administered as daily subcutaneous injections adjusted according to IGF-I levels.
Number of subjects: 19
Study 20004787 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5+ T(H)2 cells in AEG
Number of subjects: 0
Study 20004787 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5(-) T(H)2 cells in AEG
Number of subjects: 0
Study 20004787 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5+ T(H)2 cells for all foods
Number of subjects: 0
Study 20004787 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5(-) T(H)2 responses to peanut in PA
Number of subjects: 0
Study 20004787 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-5(-) T(H)2 responses to peanut in AEG
Number of subjects: 0
Study 20004787 — intervention group
Group type: COMPARATOR
Intervention: T(H)1 responses to food antigens
Number of subjects: 0
Study 20007560 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative transplantation with CD34+ peripheral-blood stem cells, mobilized by G-CSF, with 300 cGy total-body irradiation plus alemtuzumab before transplantation and sirolimus afterward
Number of subjects: 10
Study 20007664 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 16
Study 20007664 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 16
Study 20007792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in renal patients
Number of subjects: 15
Study 20007792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(-1) in renal patients
Number of subjects: 15
Study 20007792 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex 2.0 mg kg(-1) after rocuronium 0.6 mg kg(-1) in healthy controls
Number of subjects: 15
Study 20007792 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg(-1) in healthy controls
Number of subjects: 15
Study 20007809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PEG-asparaginase (2500 IU/m²) administered over 1 hour during remission induction
Number of subjects: 197
Study 20008298 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-701 (80 mg orally twice daily)
Number of subjects: 22
Study 20008626 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 300 microg
Number of subjects: 44
Study 20008626 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 700 microg
Number of subjects: 44
Study 20008626 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 1,000 microg
Number of subjects: 44
Study 20008626 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 1,500 microg
Number of subjects: 44
Study 20008626 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 44
Study 20008941 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (36 sessions)
Number of subjects: 69
Study 20008941 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 69
Study 20009044 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 4685
Study 20009044 — intervention group
Group type: COMPARATOR
Intervention: No ICD
Number of subjects: 4685
Study 20009522 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine
Number of subjects: 403
Study 20009777 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement interventions by physicians
Number of subjects: 974
Study 20010088 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 86
Study 20010317 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrilineal relatives (with the same mtDNA sequence as the proband)
Number of subjects: 672
Study 20010317 — intervention group
Group type: COMPARATOR
Intervention: Nonmatrilineal relatives (with another mtDNA sequence)
Number of subjects: 672
Study 20012045 — intervention group
Group type: EXPERIMENTAL
Intervention: VTD (Bortezomib, Thalidomide, Dexamethasone) followed by MPT (Melphalan, Prednisolone, Thalidomide)
Number of subjects: 35
Study 20012045 — intervention group
Group type: EXPERIMENTAL
Intervention: VTD followed by MPT
Number of subjects: 35
Study 20014952 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg valacyclovir oral suspension (single dose)
Number of subjects: 112
Study 20014952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg valacyclovir oral suspension (twice daily for 3-5 days)
Number of subjects: 112
Study 20014952 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg valacyclovir oral suspension (3 times daily for 5 days)
Number of subjects: 112
Study 20014952 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir oral suspension (various dosages)
Number of subjects: 112
Study 20015886 — intervention group
Group type: EXPERIMENTAL
Intervention: escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) combined with intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7)
Number of subjects: 162
Study 20015886 — intervention group
Group type: EXPERIMENTAL
Intervention: escalated imatinib and intravenous cytarabine
Number of subjects: 162
Study 20016847 — intervention group
Group type: EXPERIMENTAL
Intervention: Leishmanin skin test (LST) in Kemena
Number of subjects: 0
Study 20016847 — intervention group
Group type: COMPARATOR
Intervention: Leishmanin skin test (LST) in Sougoula
Number of subjects: 0
Study 20016847 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual incidence of Leishmania infection in Kemena (2007)
Number of subjects: 0
Study 20016847 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual incidence of Leishmania infection in Kemena (2008)
Number of subjects: 0
Study 20016847 — intervention group
Group type: COMPARATOR
Intervention: Annual incidence of Leishmania infection in Sougoula (2007)
Number of subjects: 0
Study 20016847 — intervention group
Group type: COMPARATOR
Intervention: Annual incidence of Leishmania infection in Sougoula (2008)
Number of subjects: 0
Study 20016847 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Leishmania infection in Kemena (2007)
Number of subjects: 0
Study 20016847 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of Leishmania infection in Kemena (2008)
Number of subjects: 0
Study 20018280 — intervention group
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope (TER)
Number of subjects: 249
Study 20018280 — intervention group
Group type: EXPERIMENTAL
Intervention: TER for lesions 6 mm or larger
Number of subjects: 249
Study 20018280 — intervention group
Group type: EXPERIMENTAL
Intervention: TER for lesions 10 mm or larger
Number of subjects: 249